Literature DB >> 18619121

Stereotactic body radiotherapy in the management of painful bone metastases.

Pavan Jhaveri1, Bin S Teh, Charles Bloch, Robert Amato, E Brian Butler, Arnold C Paulino.   

Abstract

More than 100,000 new cases of bone metastases are diagnosed each year, and they present an important clinical problem. They cause significant morbidity and quality-of-life issues in cancer patients. Conventional external-beam radiotherapy is currently the most common method to treat these metastases, with several randomized controlled trials showing no difference in effectiveness between multiple- and single-dosing treatment regimens. A newer technology to treat bone metastases is stereotactic body radiotherapy (SBRT), a radiation delivery method that allows for a large ablative dose to be accurately given to the target over one to a few fractions. This review details the role of SBRT in painful bone metastases, primarily in the vertebral column, but in other bony sites as well, its unique advantages and disadvantages, and its role in the treatment of tumors traditionally deemed radioresistant. Toxicity to surrounding normal tissues and patterns of local failures are also addressed.

Entities:  

Mesh:

Year:  2008        PMID: 18619121

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  6 in total

1.  Changes in cell cycle, apoptosis and necrosis following the establishment of a (125)I brachytherapy model in the spinal cord in Banna mini-pigs.

Authors:  Zuozhang Yang; Congguo Jin; Ting Chen; Hongpu Sun; Dakuan Yang; Yunchao Huang; Jin Zhang; Ruilian Zhao; Jinlei Zhang
Journal:  Oncol Lett       Date:  2011-11-17       Impact factor: 2.967

2.  Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases.

Authors:  Dawn Owen; Nadia N Laack; Charles S Mayo; Yolanda I Garces; Sean S Park; Heather J Bauer; Kathryn Nelson; Robert W Miller; Paul D Brown; Kenneth R Olivier
Journal:  Pract Radiat Oncol       Date:  2013-06-29

3.  Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.

Authors:  Michelle A Stinauer; Brian D Kavanagh; Tracey E Schefter; Rene Gonzalez; Thomas Flaig; Karl Lewis; William Robinson; Mark Chidel; Michael Glode; David Raben
Journal:  Radiat Oncol       Date:  2011-04-08       Impact factor: 3.481

Review 4.  Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.

Authors:  Onita Bhattasali; Leonard N Chen; Michael Tong; Siyuan Lei; Brian T Collins; Pranay Krishnan; Christopher Kalhorn; John H Lynch; Simeng Suy; Anatoly Dritschilo; Nancy A Dawson; Sean P Collins
Journal:  Front Oncol       Date:  2013-12-03       Impact factor: 6.244

5.  SEOM Clinical Guideline for bone metastases from solid tumours (2016).

Authors:  C Grávalos; C Rodríguez; A Sabino; M Á Seguí; J A Virizuela; A Carmona; J Cassinello; D Isla; C Jara; M Martín
Journal:  Clin Transl Oncol       Date:  2016-11-28       Impact factor: 3.405

Review 6.  Bone Metastases: An Overview.

Authors:  Filipa Macedo; Katia Ladeira; Filipa Pinho; Nadine Saraiva; Nuno Bonito; Luisa Pinto; Francisco Goncalves
Journal:  Oncol Rev       Date:  2017-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.